| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2681846 | Seminars in Oncology Nursing | 2007 | 9 Pages |
Abstract
Recent advances in the biological targeted therapies against Her2/neu, VEGF, and EGFR are now either approved therapies or are in the final stages of clinical testing. Oncology nurses can help decrease toxicities and maintain better QOL by fully understanding the mechanism of action of the drugs, expected side effects, and anticipated response to the novel regimen.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Susan Moore, Melody A. Cobleigh,